The study included 58 patients with HCV infection and prior history of treated hepatocelullar carcinoma. They all also underwent anti-HCV treatment with all-oral direct acting antivirals in four hospitals.
Here are three key insights:
1. After a median follow-up of 5.7 months, three patients died and 16 developed radiologic tumor recurrence.
2. The pattern of recurrence was intrahepatic growth, new intrahepatic lesion and infiltrative ill-defined hepatocellular carcinoma and/or extra-hepatic lesions in three patients.
3. Though the study is based in a very small cohort of patients, the results should be taken as a note of caution, the investigators note.
More articles on GI/endoscopy:
Olympus launches enhanced GI benchmarking product, HCSC issues coverage for Torax Medical’s LINX system & more — 5 GI company key notes
Mercy Health names Dr. Anton Decker chief clinical officer: 3 things to know
Gastroenterologist to know: Dr. Gary Matusow of Gastroenterology Group & Endoscopy Center of South Jersey
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
